Skip to main content Deutsch


Gastroesophageal Tumor Unit (CCC-GET)
Sorry, this content is only available in German!

Auswahl aus 2010 - 2012

(Auswahl aus 2010 - 2012)


  • Ba-Ssalamah, A., W. Matzek, S. Baroud, N. Bastati, J. Zacherl, S.F. Schoppmann, M. Hejna, F. Wrba, M. Weber, C.J. Herold, and R.M. Gore,  Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results. European radiology, 2011. 21(11): p. 2326-35.
  • Birner, P., A. Beer, U. Vinatzer, S. Stary, R. Hoftberger, N. Nirtl, F. Wrba, B. Streubel, and S.F. Schoppmann,  MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. 18(7): p. 1879-87.
  • Birner, P., B. Jesch, J. Friedrich, M. Riegler, J. Zacherl, M. Hejna, F. Wrba, A. Schultheis, and S.F. Schoppmann,  Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression. Annals of surgical oncology, 2011. 18(12): p. 3330-7.
  • Birner, P., B. Jesch, A. Schultheis, and S.F. Schoppmann,  RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its
    metastases. Clinical & experimental metastasis, 2012. 29(6): p. 551-9.
  • Bojic, M., U. Pluschnig, J. Zacherl, C.M. Thallinger, A. Ba-Ssalamah, J. Maresch, P. Datler, S.F. Schoppmann, and M. Hejna,  Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of
    Vienna. Anticancer research, 2011. 31(6): p. 2379-82.
  • Langer, F.B., S.F. Schoppmann, G. Prager, F.M. Riegler, and J. Zacherl,  Solving the problem of difficult stent removal due to tissue ingrowth in partially uncovered esophageal self-expanding metal stents. The Annals of thoracic surgery, 2010. 89(5): p. 1691-2.
  • Langer, F.B., S.F. Schoppmann, G. Prager, F. Tomaselli, U. Pluschnig, M. Hejna, R. Schmid, and J. Zacherl,  Temporary placement of self-expanding oesophageal stents as bridging for neo-adjuvant therapy. Annals of surgical oncology, 2010. 17(2): p. 470-5.
  • Maresch, J., M. Hoffmann, M. Raderer, and M. Hejna,  Stomach cancer and myositis ossificans-like lesions. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. 29(16): p. e481-2.
  • Maresch, J., S.F. Schoppmann, C.M. Thallinger, C.C. Zielinski, and M. Hejna,  Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment. Critical reviews in oncology/hematology, 2012. 82(3): p. 310-22.
  • Preusser, M., D. Capper, A. Ilhan-Mutlu, A.S. Berghoff, P. Birner, R. Bartsch, C. Marosi, C. Zielinski, M.P. Mehta, F. Winkler, W. Wick, and A. von Deimling,  Brain metastases: pathobiology and emerging targeted therapies. Acta neuropathologica, 2012. 123(2): p. 205-22.
  • Schoppmann, A., D. Tamandl, B. Herberger, F. Langle, P. Birner, S. Geleff, T. Grunberger, and S.F. Schoppmann,  Comparison of lymphangiogenesis between primary colorectal cancer and corresponding liver metastases. Anticancer research, 2011. 31(12): p. 4605-11.
  • Schoppmann, S.F., B. Jesch, J. Friedrich, G. Jomrich, F. Maroske, and P. Birner,  Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer. Clinical & experimental metastasis, 2012. 29(6): p. 615-24.
  • Schoppmann, S.F., B. Jesch, J. Friedrich, F. Wrba, A. Schultheis, U. Pluschnig, J. Maresch, J. Zacherl, M. Hejna, and P. Birner,  Expression of Her-2 in carcinomas of the esophagus. The American journal of surgical pathology, 2010. 34(12): p. 1868-73.
  • Schoppmann, S.F., B. Jesch, J. Zacherl, F. Wrba, M. Hejna, J. Maresch, F.B. Langer, M.F. Riegler, U. Pluschnig, and P. Birner,  HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases. The British journal of surgery, 2011. 98(10): p. 1408-13.
  • Schoppmann, S.F., F.B. Langer, G. Prager, and J. Zacherl,  Outcome and complications of long-term self-expanding esophageal stenting. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus / I.S.D.E, 2012.
  • Schoppmann, S.F., G. Prager, F. Langer, M. Riegler, E. Fleischman, and J. Zacherl,  Fifty-five minimally invasive Esophagectomies: a single centre experience. Anticancer research, 2009. 29(7): p. 2719-25.
  • Schoppmann, S.F., G. Prager, F.B. Langer, F.M. Riegler, B. Kabon, E. Fleischmann, and J. Zacherl,  Open versus minimally invasive esophagectomy: a single-center case controlled study. Surgical endoscopy, 2010. 24(12): p. 3044-53.
  • Silberhumer, G.R., G. Gyori, C. Burghuber, C. Neumayer, M. Riegler, R. Jakesz, G. Prager, S.F. Schoppmann, and J. Zacherl,  The value of protecting the longitudinal staple line with invaginating sutures during esophageal reconstruction by gastric tube pull-up. Digestive surgery, 2009. 26(4): p. 337-41.
  • Silberhumer, G.R., M. Hufschmid, F. Wrba, G. Gyoeri, S. Schoppmann, B. Tribl, E. Wenzl, G. Prager, F. Laengle, and J. Zacherl,  Surgery for gastrointestinal stromal tumors of the stomach. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2009. 13(7): p. 1213-9.
  • Spizzo, G., D. Ofner, A. de Vries, P. Lukas, G. Steger, U. Pluschnig, J. Zacherl, J. Widder, A. Zabernigg, G. Gastl, and G. Muhlmann,  Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study. Annals of surgical oncology, 2011. 18(3): p. 677-83.
  • Starlinger, P., L. Alidzanovic, D. Schauer, P. Brugger, S. Sommerfeldt, I. Kuehrer, S.F. Schoppmann, M. Gnant, and C. Brostjan,  Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. Disease markers, 2011. 31(2): p. 55-65.
  • Starlinger, P., P. Brugger, C. Reiter, D. Schauer, S. Sommerfeldt, D. Tamandl, I. Kuehrer, S.F. Schoppmann, M. Gnant, and C. Brostjan,  Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. Neoplasia, 2011. 13(10): p. 980-90.
  • Starlinger, P., P. Brugger, D. Schauer, S. Sommerfeldt, D. Tamandl, I. Kuehrer, S.F. Schoppmann, M. Gnant, and C. Brostjan,  Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. Neoplasia, 2011. 13(5): p. 419-27.
  • Starlinger, P., H.P. Moll, A. Assinger, C. Nemeth, K. Hoetzenecker, B. Gruenberger, T. Gruenberger, I. Kuehrer, S.F. Schoppmann, M. Gnant, and C. Brostjan,  Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. Journal of thrombosis and haemostasis : JTH, 2010. 8(8): p. 1809-19.
  • Thallinger, C.M., M. Raderer, and M. Hejna,  Esophageal cancer: a critical evaluation of systemic second-line therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. 29(35): p. 4709-14.